Harrison's Manual of Medicine 17/e

Table 186-3: FDA-Approved Indications for BMD Tests*

Table 186-3

  • Estrogen-deficient women at clinical risk of osteoporosis
  • Vertebral abnormalities on x-ray suggestive of osteoporosis (osteopenia, vertebral fracture)
  • Glucocorticoid treatment equivalent to ≥7.5 mg of prednisone, or duration of therapy >3 months
  • Primary hyperparathyroidism
  • Monitoring response to an FDA-approved medication for osteoporosis
  • Repeat BMD evaluations at >23-month intervals, or more frequently, if medically justified

*Criteria adapted from the 1998 Bone Mass Measurement Act.
Note: BMD, bone mineral density.


Chapter:
Osteoporosis and Osteomalacia

Table 186-3: FDA-Approved Indications for BMD Tests* is a sample topic found in
Harrison's Manual of Medicine.

To find other Harrison's Manual of Medicine topics
please login or purchase a subscription.

[Top]

Table 186-3: FDA-Approved Indications for BMD Tests*
Last updated: May 11, 2009
Content Manager
Related Content
Osteoporosis